Precise subtyping reveals immune heterogeneity for hormone receptor-positive breast cancer.

Zhang, Mengyan; Zhang, Xingda; Ma, Te; Wang, Cong; Zhao, Jiyun; Gu, Yue; Zhang, Yan

Zhang, Mengyan; Zhang, Xingda; Ma, Te; Wang, Cong; Zhao, Jiyun; Gu, Yue; Zhang, Yan.

Afiliação

Zhang M; School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150001, China.
Zhang X; Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China.
Ma T; School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150001, China.
Wang C; School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150001, China.
Zhao J; School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150001, China.
Gu Y; School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150001, China.
Zhang Y; School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150001, China; College of Pathology, Qiqihar Medical University, Qiqihar, 161042, China. Electronic address: zhangtyo@hit.edu.cn.

Comput Biol Med ; 163: 107222, 2023 09.

Article em En | MEDLINE | ID: mdl-37413851

Assuntos

Neoplasias; Resultado do Tratamento

Palavras-chave

Conserved subgroups; DNA methylation; HR+ breast cancer; Immune microenvironment; Individualized treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google